Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo.
Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo. The follow-on was approved by the FDA earlier this month.
According to Pfenex, the study included 102 untrained participants, 52 of whom were patients with osteoporosis and 50 of whom were caregivers. Of the 18 critical tasks assessed, patients using the follow-on had fewer user errors or the same number of errors for 12 (67%) of those tasks. Among caregivers, there were equal numbers of user errors or fewer errors for 15 (83%) of the tasks.
No error difference, in either of the user groups, exceeded the prespecified maximum allowable difference.
In a statement, Pfenex’s chief executive officer, Eef Schimmelpennink, said that the outcome of the study “demonstrates noninferiority between the user interfaces of our product and Forteo,” and that the company will present the data to the FDA as part of a package that the regulator will review to evaluate therapeutic equivalence of the product with its reference.
Because PF708 was approved under the 505(b)(2) approval pathway instead of the biosimilar approval pathway, Pfenex can seek pharmacy-level substitutability for the product without having to undertake the kinds of extra clinical studies that a biosimilar would be subject to if seeking an interchangeable designation; because it is a follow-on and not a biosimilar, PF708 will be evaluated for a determination therapeutic equivalence rather than an interchangeable designation.
When the follow-on was first approved, Schimmelpennink noted that, in order to optimize patient and payer impact, Pfenex’s partner Alvogen will launch PF708 once the FDA has made its decision on therapeutic equivalence for the product.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.